India, Dec. 22 -- Emcure Pharmaceuticals announced the commercial launch of Poviztra(R), semaglutide injection, across India. With this launch Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra(R), a second brand of Novo Nordisk's Semaglutide injection for weight management. Available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dosing of 2.4 mg, the products will be priced starting Rs 8790/- per month (4 weekly doses). It comes in a state-of-the-art pen device that provides the convenience of simple administration of precise dosing.Semaglutide injection (Poviztra(R)) is supported by extensive clinical evidence from the STEP and SELECT clinical t...